Search Grant Opportunities

Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)

ID: RFA-DK-28-113 • Type: Forecasted
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Sign in to upload a capability statement or catalogue for your company

Analyze Opportunity
Generate a Draft
Loading

Description

This NOFO will support research using human-relevant New Approach Methodologies (NAMs) to advance understanding of the earliest events that initiate and drive Type 1 Diabetes (T1D). Projects will use human cells and tissues and innovative experimental and computational approaches including organoids, microphysiological systems, and other advanced human-relevant models to investigate cellular and molecular mechanisms involved in T1D initiation and early disease progression. The research is expected to identify and validate early biomarkers and therapeutic targets and advance new strategies to prevent or interrupt disease progression before substantial pancreatic beta cell loss occurs.

Funded projects will become part of the Human Islet Research Network (HIRN), providing a collaborative environment that brings together complementary expertise, technologies, human biological resources, and datasets. Awardees will be expected to participate in collaborative activities, share tools and data, coordinate the use of scarce human pancreatic tissues, and promote harmonization and interoperability of approaches and datasets where appropriate. Through this coordinated research effort, the initiative seeks to overcome barriers that have limited progress by individual laboratories and accelerate the translation of discoveries about early human T1D into biomarkers, therapeutic targets, and ultimately preventive or treatment strategies.

This NOFO will support research using human-relevant New Approach Methodologies (NAMs) to advance understanding of the earliest events that initiate and drive Type 1 Diabetes (T1D). Projects will use human cells and tissues and innovative experimental and computational approaches including organoids, microphysiological systems, and other advanced human-relevant models to investigate cellular and molecular mechanisms involved in T1D initiation and early disease progression. The research is expected to identify and validate early biomarkers and therapeutic targets and advance new strategies to prevent or interrupt disease progression before substantial pancreatic beta cell loss occurs.

Funded projects will become part of the Human Islet Research Network (HIRN), providing a collaborative environment that brings together complementary expertise, technologies, human biological resources, and datasets. Awardees will be expected to participate in collaborative activities, share tools and data, coordinate the use of scarce human pancreatic tissues, and promote harmonization and interoperability of approaches and datasets where appropriate. Through this coordinated research effort, the initiative seeks to overcome barriers that have limited progress by individual laboratories and accelerate the translation of discoveries about early human T1D into biomarkers, therapeutic targets, and ultimately preventive or treatment strategies.

Overview

Category of Funding
Health
Funding Instruments
Cooperative Agreement
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
On 11/5/26 the National Institutes of Health forecasted grant opportunity RFA-DK-28-113 for Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed) with funding of $12.0 million. The grant will be issued under grant program 93.855 Allergy and Infectious Diseases Research. It is expected that 12 total grants will be made.

Timing

Forecast Posted Date
Est. Application Posting Date
Est. Synopsis Response Date
Forecasted
Last Updated
Version
1

Eligibility

Eligible Applicants
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Small businesses
Native American tribal governments (Federally recognized)
City or township governments
Independent school districts
Special district governments
Public and State controlled institutions of higher education
Private institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
County governments
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Additional Info
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Award Sizing

Ceiling
Not Listed
Floor
Not Listed
Estimated Program Funding
$12,000,000
Estimated Number of Grants
12

Contacts

Contact
Division of Digestive Diseases and Nutrition
Contact Email

Documents

Posted documents for RFA-DK-28-113

Opportunity Assistant


Analyze Opportunity

Generate a Draft

Potential Applicants and Partners

Awardees that have recently won grants similar to RFA-DK-28-113

Incumbent or Similar Grants

Grants similar to RFA-DK-28-113

Similar Active Opportunities

Open grant opportunities similar to RFA-DK-28-113

Experts for Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)

Recommended subject matter experts available for hire